A Phase 2a, Multicenter, Proof-of-Concept Clinical Trial to Evaluate Efficacy and Safety of BSI-045B mAb Injection as Monotherapy or Add-on Therapy With Dupilumab in Patients With Moderate to Severe Atopic Dermatitis
Latest Information Update: 31 Oct 2024
At a glance
- Drugs Bosakitug (Primary) ; Dupilumab
- Indications Atopic dermatitis
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Acronyms ADAMANT
- Sponsors Biosion
Most Recent Events
- 28 Oct 2024 Status changed from recruiting to completed.
- 11 Jun 2024 Key results presented in a Biosion Media Release.
- 11 Jun 2024 According to a Biosion media release, key results from the ADAMANT study at the Revolutionizing Atopic Dermatitis conference in Chicago, IL.